3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Leukemia, Myeloid, Acute
100
Leukemia
36
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Myelodysplastic Syndromes
17
Leukemia, Monocytic, Acute
14
Leukemia, Myelomonocytic, Acute
13
Leukemia, Erythroblastic, Acute
12
Leukemia, Megakaryoblastic, Acute
11
Congenital Abnormalities
11
Leukemia, Promyelocytic, Acute
9
Recurrence
8
Leukemia, Biphenotypic, Acute
7
Carcinoma, Hepatocellular
7
Leukemia, Myelomonocytic, Chronic
6
Myeloproliferative Disorders
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Anemia, Refractory, with Excess of Blasts
5
Lymphoma
4
Blast Crisis
4
Neoplasm, Residual
3
Lymphoma, Large B-Cell, Diffuse
3
Liver Neoplasms
3
Leukemia, Myeloid, Chronic-Phase
3
Leukemia, Myeloid, Accelerated Phase
3
Leukemia, Eosinophilic, Acute
3
Leukemia, Basophilic, Acute
3
Lymphoma, Non-Hodgkin
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Follicular
2
Lung Neoplasms
2
Interventions
Cyclophosphamide
10
fludarabine
5
Radiotherapy
5
Doxorubicin
5
Gemcitabine
3
sargramostim
2
fludarabine phosphate
2
aldesleukin
2
Sunitinib
2
Radiation Dose Hypofractionation
2
Nivolumab
2
Leukapheresis
2
Ifosfamide
2
Docetaxel
2
Decitabine
2
Dacarbazine
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
trofosfamide
1
tremelimumab
1
temsirolimus
1
sotigalimab
1
ribociclib
1
poly ICLC
1
pembrolizumab
1
pegfilgrastim
1
pazopanib
1
pasireotide
1
olaparib
1
lutetium Lu 177 dotatate
1
liposomal doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Sarcoma, Synovial
×
Idarubicin
×
Clear all
NCT00876031
2022-11-08
CWS-2007-HR
University Hospital Tuebingen
Phase 3
Completed
195 enrolled